Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTANASDAQ:FLXNNASDAQ:INDVNASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$12.38+2.8%$12.58$8.46▼$19.09$1.65B1.48703,255 shs1.04 million shsFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/AINDVIndivior$13.89-0.3%$11.30$7.33▼$16.98$1.92B0.661.10 million shs555,885 shsSUPNSupernus Pharmaceuticals$32.03-2.3%$32.02$25.55▼$40.28$1.79B0.71480,742 shs590,662 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals0.00%+3.86%-1.67%-27.77%+27.63%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%INDVIndivior0.00%-1.28%+25.47%+43.49%-17.57%SUPNSupernus Pharmaceuticals0.00%-3.38%-1.39%+2.46%+18.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTACentessa Pharmaceuticals3.6309 of 5 stars4.52.00.00.02.63.30.6FLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AINDVIndivior2.5673 of 5 stars1.65.00.00.03.41.71.9SUPNSupernus Pharmaceuticals2.1417 of 5 stars2.21.00.04.12.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 3.00Buy$27.89125.27% UpsideFLXNFlexion Therapeutics 0.00N/AN/AN/AINDVIndivior 3.25Buy$15.007.99% UpsideSUPNSupernus Pharmaceuticals 2.33Hold$36.0012.39% UpsideCurrent Analyst Ratings BreakdownLatest FLXN, CNTA, INDV, and SUPN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025CNTACentessa PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.005/8/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$6.005/8/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.003/31/2025CNTACentessa PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$38.003/26/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$15M110.23N/AN/A$2.42 per share5.12FLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82INDVIndivior$1.17B1.64$2.81 per share4.94N/A∞SUPNSupernus Pharmaceuticals$668.00M2.68$1.47 per share21.83$16.87 per share1.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$151.09M-$1.81N/AN/AN/AN/A-52.13%-38.01%8/12/2025 (Estimated)FLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AINDVIndivior$2M-$0.31N/A8.12N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)SUPNSupernus Pharmaceuticals$1.32M$1.1129.9322.24N/A9.16%7.79%5.67%8/5/2025 (Estimated)Latest FLXN, CNTA, INDV, and SUPN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.1521.5221.52FLXNFlexion TherapeuticsN/A4.384.05INDVIndiviorN/A0.830.65SUPNSupernus PharmaceuticalsN/A2.201.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%FLXNFlexion Therapeutics90.01%INDVIndivior60.33%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals7.09%FLXNFlexion Therapeutics9.13%INDVIndiviorN/ASUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200133.56 million116.56 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableSUPNSupernus Pharmaceuticals58055.99 million50.08 millionOptionableFLXN, CNTA, INDV, and SUPN HeadlinesRecent News About These CompaniesSupernus Pharmaceuticals (NASDAQ:SUPN) and Nabriva Therapeutics (NASDAQ:NBRV) Financial SurveyJune 14 at 1:49 AM | americanbankingnews.comWedge Capital Management L L P NC Acquires 13,955 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 10, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Two Sigma Investments LPJune 7, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Acquires 11,304 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 5, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.62 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 5, 2025 | marketbeat.comMillennium Management LLC Trims Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 5, 2025 | marketbeat.comBranded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)June 2, 2025 | msn.comJefferies Financial Group Inc. Buys Shares of 24,600 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 31, 2025 | marketbeat.comVoloridge Investment Management LLC Cuts Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 31, 2025 | marketbeat.comSupernus Pharmaceuticals Partners with Jay Glazer for ADHD Awareness Series Featuring Insights from His Journey with QelbreeMay 29, 2025 | quiverquant.comJay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus PharmaceuticalsMay 29, 2025 | globenewswire.comSupernus to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comSupernus Announces Paragraph IV ANDA Filings for Qelbree®May 28, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), 908 Devices (MASS) and Supernus Pharmaceuticals (SUPN)May 24, 2025 | theglobeandmail.comWoodline Partners LP Raises Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys Shares of 26,828 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 24, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Deutsche Bank AGMay 22, 2025 | marketbeat.comSupernus Pharmaceuticals Partners with Busy Philipps for "Ms. Represented" Campaign to Empower Women with ADHDMay 20, 2025 | quiverquant.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Systematic Financial Management LPMay 20, 2025 | marketbeat.comCaptrust Financial Advisors Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 20, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Ameriprise Financial Inc.May 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLXN, CNTA, INDV, and SUPN Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$12.38 +0.34 (+2.82%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$12.36 -0.03 (-0.20%) As of 06/13/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Flexion Therapeutics NASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Indivior NASDAQ:INDV$13.89 -0.04 (-0.29%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$13.88 -0.01 (-0.04%) As of 06/13/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Supernus Pharmaceuticals NASDAQ:SUPN$32.03 -0.74 (-2.26%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$31.80 -0.23 (-0.70%) As of 06/13/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
